Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Verschraegen
C F
CF
Secion of Gynecologic and Medical Therapeutics, Department of Gynecology Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. cverschr@mdanderson.org
Levenback
C
C
Vincent
M
M
Wolf
J
J
Bevers
M
M
Loyer
E
E
Kudelka
A P
AP
Kavanagh
J J
JJ
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000627:therapeutic use; D043823:Taxoids; D019772:Topotecan / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D001952:Bridged-Ring Compounds; D017671:Platinum Compounds; D043823:Taxoids; C080625:taxane; D019772:Topotecan; C095887:exatecan; D002166:Camptothecin